Last reviewed · How we verify

Sorafenib + Pravastatin — Competitive Intelligence Brief

Sorafenib + Pravastatin (Sorafenib + Pravastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor + HMG-CoA reductase inhibitor. Area: Oncology.

phase 3 Multi-kinase inhibitor + HMG-CoA reductase inhibitor RAF, VEGFR, PDGFR (sorafenib); HMG-CoA reductase (pravastatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sorafenib + Pravastatin (Sorafenib + Pravastatin) — Centre Hospitalier Universitaire Dijon. This combination pairs sorafenib, a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, with pravastatin, a statin that may enhance anti-tumor effects and reduce cardiovascular risk.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sorafenib + Pravastatin TARGET Sorafenib + Pravastatin Centre Hospitalier Universitaire Dijon phase 3 Multi-kinase inhibitor + HMG-CoA reductase inhibitor RAF, VEGFR, PDGFR (sorafenib); HMG-CoA reductase (pravastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor + HMG-CoA reductase inhibitor class)

  1. Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sorafenib + Pravastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/sorafenib-pravastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: